{"id":309,"date":"2026-08-04T12:29:12","date_gmt":"2026-08-04T10:29:12","guid":{"rendered":"https:\/\/www.pqra.gr\/biosimilars-in-europe-interchangeability-and-the-new-tailored-clinical-approach\/"},"modified":"2026-08-04T12:29:31","modified_gmt":"2026-08-04T10:29:31","slug":"biosimilars-in-europe-interchangeability-and-the-new-tailored-clinical-approach","status":"publish","type":"post","link":"https:\/\/www.pqra.gr\/el\/biosimilars-in-europe-interchangeability-and-the-new-tailored-clinical-approach\/","title":{"rendered":"Biosimilars in Europe: Interchangeability and the New Tailored Clinical Approach"},"content":{"rendered":"

By 2026 the European biosimilar framework has matured from cautious, case-by-case review into one of the most confident regulatory systems in the world — and it is about to become faster still. With interchangeability now formally endorsed across the Union and a landmark reflection paper trimming the clinical data burden, companies developing biosimilars for the European market face a genuinely new landscape.<\/strong><\/p>\n\n

A maturing regulatory framework<\/h2>\n

The EU has authorised biosimilars since 2006 and has now approved well over 100 products, backed by more than 15 years of post-authorisation safety monitoring. Approval rests on a comparability exercise rather than a full independent dossier: the applicant must demonstrate that the biosimilar is highly similar to its reference medicine in terms of quality, biological activity, safety and efficacy. Analytical characterisation sits at the foundation of that exercise, with clinical data used to confirm — not re-establish — the profile of the molecule.<\/p>\n\n

Interchangeability: settled at EU level<\/h2>\n

In a joint statement of September 2022, the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) confirmed that biosimilars approved in the EU are interchangeable with their reference medicine or with an equivalent biosimilar. In practice this means a reference product can be replaced by a biosimilar without a patient experiencing any change in clinical effect.<\/p>\n

One important caveat remains: while the science<\/em> of interchangeability is settled centrally, decisions on switching and automatic substitution at pharmacy level stay a national competence. Rules differ markedly between member states, so a pan-European launch still demands country-by-country planning — including in Greece.<\/p>\n\n

The tailored clinical approach<\/h2>\n

The most significant recent shift is EMA’s move to streamline clinical requirements. Following a concept paper in November 2023 and a draft published in April 2025, the CHMP adopted its Reflection paper on a tailored clinical approach in biosimilar development<\/em> in March 2026. Its central conclusions include:<\/p>\n